Bibliographic record
Abstract
Canada's Drug Agency (CDA-AMC) recommends that public drug plans reimburse Rystiggo as an add-on therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody positive and for whom symptoms persist despite conventional therapy with acetylcholinesterase inhibitors (AChEIs), corticosteroids, and/or nonsteroidal immunosuppressive therapies (NSISTs) if certain conditions are met. Rystiggo should only be covered to treat patients who have a diagnosis of class II to IV gMG based on the Myasthenia Gravis Foundation of America (MGFA) system, have tested positive for AChR or MuSK antibodies, and have a Myasthenia Gravis Activities of Daily Living (MG-ADL) scale score of at least 3 with at least 3 points for symptoms not related to their eyes. Rystiggo should only be covered to treat patients if their symptoms persist despite a stable dose of conventional therapy with AChEIs, corticosteroids, and/or NSISTs. Rystiggo should not be reimbursed when given during a gMG exacerbation (i.e., a moment when the patient experiences weakness in some or all muscles, without needing assistance to breath) or crisis (i.e., a moment when respiratory muscles are too weak, limiting air flow in and out of the lungs and, as a result, the patient is unable to breathe), or within 6 months of thymectomy (i.e., surgical removal of the thymus gland). Rystiggo should only be reimbursed if prescribed by or in consultation with a neurologist with expertise in managing patients with gMG, and the total cost of Rystiggo should not exceed the total drug cost with the least costly advanced treatments for gMG. Rystiggo should not be used concomitantly with rituximab, efgartigimod alfa, and/or complement inhibitors such as eculizumab.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".